No - Biochemical Screening Must Precede Imaging for Pheochromocytoma Diagnosis
Imaging should generally be performed only after biochemical confirmation of pheochromocytoma, not as a standalone diagnostic approach. This recommendation is consistent across multiple high-quality guidelines to avoid identifying incidental adrenal masses that are not pheochromocytomas and to prevent unnecessary procedures 1, 2.
The Evidence-Based Diagnostic Sequence
Step 1: Biochemical Testing First
The diagnostic algorithm begins with biochemical screening when pheochromocytoma is clinically suspected. The most sensitive and specific initial test is plasma free metanephrines and normetanephrines (sensitivity 97-100%, specificity 85-89%) 3, 2. Alternative options include:
- 24-hour urinary fractionated metanephrines (sensitivity ~95%) 1
- 24-hour urinary total metanephrines and catecholamines (sensitivity 90-95%) 1
Step 2: Imaging Only After Biochemical Confirmation
Once biochemical evidence is established, proceed to imaging for tumor localization 1, 2. The Hypertension Canada 2020 guidelines explicitly state: "Imaging should generally be performed only after biochemical confirmation of disease" 1. This approach prevents the identification of incidentalomas that would lead to unnecessary workup and potential false-positive results 1.
Why This Sequence Matters
Avoiding False Positives
Performing imaging first risks identifying adrenal incidentalomas that may have atypical imaging characteristics but are not pheochromocytomas. The guidelines specifically warn that "atypical imaging results for pheochromocytoma" should raise concern for false-positive biochemical results 1. By establishing biochemical evidence first, you avoid this diagnostic confusion.
The Exception: When Imaging Characteristics Are Highly Specific
Recent research suggests a nuanced exception to this rule. Studies demonstrate that adrenal incidentalomas with unenhanced CT attenuation ≤10 Hounsfield Units (HU) have an extremely low likelihood of being pheochromocytomas:
- One multicenter study of 222 pheochromocytomas found only 1 tumor with ≤10 HU, yielding a sensitivity of 99.6% for the >10 HU threshold 4
- A retrospective study of 174 patients found zero pheochromocytomas among 146 incidentalomas with <10 HU 5
- Similarly, MRI features showing hypointensity or isointensity on T2-weighted sequences AND signal loss on out-of-phase sequences had zero pheochromocytomas in one study 6
However, these imaging-based exclusion criteria should only be applied to incidentally discovered adrenal masses in asymptomatic patients, not as a primary diagnostic strategy when pheochromocytoma is clinically suspected.
Clinical Scenarios Requiring Biochemical Screening
You should suspect pheochromocytoma and initiate biochemical testing in:
- Hypertensive patients with classic symptoms: paroxysmal or severe hypertension (≥180/110 mmHg), headaches, palpitations, sweating, panic attacks, or pallor 7
- Resistant hypertension refractory to usual therapy 7
- Adrenal incidentalomas with >10 HU on unenhanced CT 5, 4, 8
- Young patients (<50 years) with hypertension 1
- Hereditary syndromes: von Hippel-Lindau, MEN2, neurofibromatosis type 1, familial paraganglioma 3
- NF1 patients who are hypertensive, over 30 years, pregnant, or have paroxysmal symptoms 9
Managing Borderline Results
When biochemical results are borderline (less than 2-fold elevation above normal) or potentially false-positive, repeat testing or clonidine suppression testing should be performed before proceeding to imaging 1. This prevents identifying incidentalomas in patients who don't actually have pheochromocytoma.
Common causes of false-positive biochemical results include:
- Interfering medications (tricyclic antidepressants, decongestants, acetaminophen)
- Incorrect patient preparation for plasma metanephrines
- Acute illness or hospitalization
- Only one abnormal test in a panel of assays 1
The Bottom Line
The standard of care requires biochemical confirmation before imaging, with the narrow exception of incidentally discovered adrenal masses with benign imaging characteristics (≤10 HU on unenhanced CT or specific MRI features) in asymptomatic patients. This approach maximizes diagnostic accuracy while minimizing unnecessary procedures and false-positive results that could lead to inappropriate surgical intervention.